cas 85426-71-7|| where to buy 4,6-Dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine

Product Name:4,6-Dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine

IUPAC Name:[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-{4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}oxolan-2-yl]methyl acetate

Packing Unit	Available Stock	Price($)	Quantity
CM1075895-1g	in stock	ŗĲƥ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 85426-71-7 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:85426-71-7; Molecular Formula:C16H16Cl2N4O7; Melting Point:-; Smiles Code:O(C(C)=O)[C@H]1[C@@H](O[C@H](COC(C)=O)[C@H]1OC(C)=O)N2C=3C(C=N2)=C(Cl)N=C(Cl)N3; Density:

: Catalog Number:CM1075895; Molecular Weight:447.23; Boiling Point:; MDL No:; Storage:

: Nucleosides and Nucleotides; Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.; nucleoside manufacturer; As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: ORIC-533; ORIC-533 is a potential best-in-class, oral inhibitor of CD73 developed by ORIC Pharmaceuticals which is currently in a Ph. Ib trial for the treatment of relapsed/refractory multiple myeloma (MM). It inhibits the CD73-mediated conversion of AMP to adenosine which generates an immunosuppressive tumor microenvironment and has the potential to be a next-generation immunotherapy. The in-depth use of co-crystal structures led the team to discover a novel set of phosphonate bioisosteres which were able to achieve bioavailability for a highly polar scaffold. The structure and discovery story of ORIC-533 were recently presented at the ACS Spring 2024 Meeting in New Orleans.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.